Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1

被引：41

作者：

Zhang, Zhongsheng ^{[2
]}

Ojo, Kayode K. ^{[1
]}

Johnson, Steven M. ^{[3
]}

Larson, Eric T. ^{[2
]}

He, Penqing ^{[1
]}

Geiger, Jennifer A. ^{[4
]}

Castellanos-Gonzalez, Alejandro ^{[5
]}

White, A. Clinton, Jr. ^{[5
]}

Parsons, Marilyn ^{[4
]}

Merritt, Ethan A. ^{[2
]}

Maly, Dustin J. ^{[3
]}

Verlinde, Christophe L. M. J. ^{[2
]}

Van Voorhis, Wesley C. ^{[1
]}

Fan, Erkang ^{[2
]}

机构：

[1] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA

[2] Univ Washington, Dept Biochem, Seattle, WA 98195 USA

[3] Univ Washington, Dept Chem, Seattle, WA 98195 USA

[4] Seattle Biomed Res Inst, Seattle, WA 98109 USA

[5] Univ Texas Med Branch, Dept Internal Med, Div Infect Dis, Galveston, TX 77555 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 16期

基金：

美国国家卫生研究院;

关键词：

Cryptosporidium parvum; Toxoplasma gondii; Calcium-dependent protein kinase-1; Enzyme inhibitor; Selectivity; DESIGN; POTENT; CDPK1;

D O I：

10.1016/j.bmcl.2012.06.050

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Calcium-dependent protein kinase-1 (CDPK1) from Cryptosporidium parvum (CpCDPK1) and Toxoplasma gondii (TgCDPK1) have become attractive targets for discovering selective inhibitors to combat infections caused by these protozoa. We used structure-based design to improve a series of benzoylbenzimidazole-based compounds in terms of solubility, selectivity, and potency against CpCDPK1 and TgCDPK1. The best inhibitors show inhibitory potencies below 50 nM and selectivity well above 200-fold over two human kinases with small gatekeeper residues. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：5264 / 5267

页数：4

共 39 条

[31] Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G
Bansal, Abhisheka
Ojo, Kayode K.
Mu, Jianbing
Maly, Dustin J.
Van Voorhis, Wesley C.
Miller, Louis H.
MBIO, 2016, 7 (06):
[32] Immunoinformatics studies and design of a novel multi-epitope peptide vaccine against Toxoplasma gondii based on calcium-dependent protein kinases antigens through an in-silico analysis
Ghaffari, Ali Dalir
Rahimi, Fardin
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2024, 13 (02) : 146 - 154
[33] Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis
Vidadala, Rama Subba Rao
Rivas, Kasey L.
Ojo, Kayode K.
HuIverson, Matthew A.
Zambriski, Jennifer A.
Bruzual, Igor
Schultz, Tracey L.
Huang, Wenlin
Zhang, Zhongsheng
Scheele, Suzanne
DeRocher, Amy E.
Choi, Ryan
Barrett, Lynn K.
Siddaramaiah, Latha Kallur
Hol, Wim G. J.
Fan, Erkang
Merritt, Ethan A.
Parsons, Marilyn
Freiberg, Gail
Marsh, Kennan
Kempf, Dale J.
Carruthers, Vern B.
Isoherranen, Nina
Doggett, J. Stone
Van Voorhis, Wesley C.
Maly, Dustin J.
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (13) : 6531 - 6546
[34] Evaluation of protective immunity induced by recombinant calcium-dependent protein kinase 1 (TgCDPK1) protein against acute toxoplasmosis in mice
Huang, Si-Yang
Chen, Kai
Wang, Jin-Lei
Yang, Bin
Zhu, Xing-Quan
MICROBIAL PATHOGENESIS, 2019, 133
[35] Pharmacophore modeling, 3D-QSAR, and molecular docking study on naphthyridine derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1
Kirubakaran, Palani
Muthusamy, Karthikeyan
Singh, Kh Dhanachandra
Nagamani, Selvaraman
MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (08) : 3812 - 3822
[36] Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy
Zhu, Jing
Xin, Meng
Xu, Congcong
He, Yuan
Zhang, Wannian
Wang, Zhibin
Zhuang, Chunlin
ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 3193 - 3205
[37] Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2
Fujimoto, Kazuki
Matsuoka, Eriko
Asada, Naoya
Tadano, Genta
Yamamoto, Takahiko
Nakahara, Kenji
Fuchino, Kouki
Ito, Hisanori
Kanegawa, Naoki
Moechars, Diederik
Gijsen, Harrie J. M.
Kusakabe, Ken-ichi
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) : 5080 - 5095
[38] 7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium- Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors
Vidadala, Rama S. R.
Golkowski, Martin
Hulverson, Matthew A.
Choi, Ryan
McCloskey, Molly C.
Whitman, Grant R.
Huang, Wenlin
Arnold, Samuel L. M.
Barrett, Lynn K.
Fan, Erkang
Merritt, Ethan A.
Van Voorhis, Wesley C.
Ojo, Kayode K.
Maly, Dustin J.
ACS INFECTIOUS DISEASES, 2018, 4 (04): : 516 - 522
[39] Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
Reich, Siegfried H.
Sprengeler, Paul A.
Chiang, Gary G.
Appleman, James R.
Chen, Joan
Clarine, Jeff
Eam, Boreth
Ernst, Justin T.
Han, Qing
Goel, Vikas K.
Han, Edward Z. R.
Huang, Vera
Hung, Ivy N. J.
Jemison, Adrianna
Jessen, Katti A.
Molter, Jolene
Murphy, Douglas
Neal, Melissa
Parker, Gregory S.
Shaghafi, Michael
Sperry, Samuel
Staunton, Jocelyn
Stumpf, Craig R.
Thompson, Peggy A.
Tran, Chinh
Webber, Stephen E.
Wegerski, Christopher J.
Zheng, Hong
Webster, Kevin R.
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (08) : 3516 - 3540

← 1 2 3 4 →